[go: up one dir, main page]

EP1012333A1 - ISOLEMENT D'UN NOUVEAU GENE p23 DU FACTEUR DE SENESCENCE - Google Patents

ISOLEMENT D'UN NOUVEAU GENE p23 DU FACTEUR DE SENESCENCE

Info

Publication number
EP1012333A1
EP1012333A1 EP98938406A EP98938406A EP1012333A1 EP 1012333 A1 EP1012333 A1 EP 1012333A1 EP 98938406 A EP98938406 A EP 98938406A EP 98938406 A EP98938406 A EP 98938406A EP 1012333 A1 EP1012333 A1 EP 1012333A1
Authority
EP
European Patent Office
Prior art keywords
cells
cell
seq
senescent
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98938406A
Other languages
German (de)
English (en)
Other versions
EP1012333A4 (fr
Inventor
Karen Swisshelm
Suzanne Hosier
Manfred Kubbies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of EP1012333A1 publication Critical patent/EP1012333A1/fr
Publication of EP1012333A4 publication Critical patent/EP1012333A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • This enzyme's presence can be detected easily by providing cells with a substrate that yields a blue-colored product upon enzymatic cleavage.
  • these investigators observed an age-dependent rise in this senescence-associated ⁇ -galactosidase in human skin, suggesting that the accumulation of the enzyme provides a marker for senescence in fibroblasts and keratinocytes in the skin and perhaps other epithelial tissues.
  • senescence may have evolved as a mechanism for tumor suppression, and that aging is an indirect effect of this circumstance. Because constraints on growth control are absent from tumor cells, such cells most likely have switched off the expression of genes whose products promote or maintain the senescent state. For example, in vitro studies have indicated that senescence can be partially circumvented by the inactivation of tumor suppressor proteins such as the retinoblastoma tumor suppressor gene RBI (Weinberg, Cell 81:323-330, 1995). This suggests the possibility that the loss of functional tumor suppressor genes in vivo could permit cells to gain a replicative advantage and eventually to undergo immortalization.
  • tumor suppressor proteins such as the retinoblastoma tumor suppressor gene RBI (Weinberg, Cell 81:323-330, 1995). This suggests the possibility that the loss of functional tumor suppressor genes in vivo could permit cells to gain a replicative advantage and eventually to undergo immortalization.
  • a novel gene has been identified that is expressed at high levels in senescent cells.
  • a cDNA corresponding to the novel gene has been isolated and sequenced and found to contain an open reading frame encoding a protein having a deduced molecular weight of 23 kilodaltons (kDa) (SEQ ID NO: l).
  • kDa kilodaltons
  • this gene has been named "p23.”
  • Messenger RNA transcribed from p23 is reproducibly detectable at higher levels in senescent than in proliferating cultured normal human mammary epithelial cells.
  • p23 The function of p23 is not known, but analysis of its deduced amino acid sequence (SEQ ID NO:2) suggests that it belongs to a family of transmembrane proteins known as the "PMP 22" family or "epithelial membrane protein” (EMP) family (e.g., see Taylor et al., J. Biol. Chem. 270:28824-28833, 1995; Lobsiger et al., Genomics 36:379-387, 1996; Taylor and Suter, Gene 175:115-120. 1996).
  • PMP 22 family
  • EMP epidermal membrane protein
  • Immunospecific reagents capable of specifically binding p23 may be produced by hybridoma or by repeated injection of the purified protein or selected peptides derived from p23 in combination with an appropriate adjuvant (e.g., Freund's, ISCOMs, or the like) into a suitable animal such as a rabbit, sheep, or goat.
  • an appropriate adjuvant e.g., Freund's, ISCOMs, or the like
  • Therapeutic applications include binding partners that inhibit the binding of p23 to ligands that normally bind to it. thus promoting cell proliferation in the treated cell.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne une molécule isolée d'acide nucléique relative à la sénescence codant un polypeptide de 23 kilodaltons (p23), des procédés servant à exprimer ce polypeptide de 23 kilodaltons dans des cultures de cellules, des polypeptides p23 de recombinaison, des vecteurs d'expression et des cellules hôtes exprimant p23, ainsi que des anticorps contre p23. Elle concerne également des procédés permettant de mettre en application p23 afin de moduler la sénescence, et de déterminer l'expression de p23 dans des spécimens biologiques.
EP98938406A 1997-08-08 1998-08-05 ISOLEMENT D'UN NOUVEAU GENE p23 DU FACTEUR DE SENESCENCE Withdrawn EP1012333A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90887397A 1997-08-08 1997-08-08
US908873 1997-08-08
PCT/US1998/016343 WO1999007893A1 (fr) 1997-08-08 1998-08-05 ISOLEMENT D'UN NOUVEAU GENE p23 DU FACTEUR DE SENESCENCE

Publications (2)

Publication Number Publication Date
EP1012333A1 true EP1012333A1 (fr) 2000-06-28
EP1012333A4 EP1012333A4 (fr) 2003-01-02

Family

ID=25426353

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98938406A Withdrawn EP1012333A4 (fr) 1997-08-08 1998-08-05 ISOLEMENT D'UN NOUVEAU GENE p23 DU FACTEUR DE SENESCENCE

Country Status (9)

Country Link
EP (1) EP1012333A4 (fr)
JP (1) JP2001512698A (fr)
KR (1) KR20010022741A (fr)
CN (1) CN1270637A (fr)
AU (1) AU8693598A (fr)
BR (1) BR9811865A (fr)
CA (1) CA2296598A1 (fr)
TR (1) TR200000331T2 (fr)
WO (1) WO1999007893A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE463566T1 (de) * 2000-01-21 2010-04-15 Polymun Scient Immunbio Forsch Tumor- und seneszenzsmarker
AU750296B2 (en) * 2000-06-23 2002-07-11 F. Hoffmann-La Roche Ag Antibodies against SEMP1, methods for their production and uses thereof
AU2001237938A1 (en) * 2000-09-20 2002-04-02 Human Genome Sciences, Inc. 21 human secreted proteins
US7125663B2 (en) 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
DK2789684T3 (en) * 2008-05-23 2017-02-20 Siwa Corp Methods and compositions for facilitating regeneration
EP3511017A1 (fr) 2010-09-27 2019-07-17 Siwa Corporation Élimination sélective de cellules modifiées par l'âge pour le traitement de l'athérosclérose
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
AU2015318036B2 (en) 2014-09-19 2021-07-01 Siwa Corporation Anti-AGE antibodies for treating inflammation and auto-immune disorders
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
EP4067386A1 (fr) 2016-02-19 2022-10-05 Siwa Corporation Procédé et composition pour traiter le cancer, tuer des cellules du cancer métastatique et prévenir des métastases cancéreuses à l'aide d'anticorps pour produits finaux de glycosylation avancée (rage)
US11958900B2 (en) 2016-04-15 2024-04-16 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017222535A1 (fr) 2016-06-23 2017-12-28 Siwa Corporation Vaccins pour l'utilisation dans le traitement de diverses maladies et troubles
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
EP3609923A1 (fr) 2017-04-13 2020-02-19 Siwa Corporation Anticorps monoclonal humanisé de produit final de glycation avancée
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580726A (en) * 1994-04-29 1996-12-03 Geron Corporation Method and Kit for enhanced differential display
US5744300A (en) * 1993-03-24 1998-04-28 Geron Corporation Methods and reagents for the identification and regulation of senescence-related genes
JP2001512681A (ja) * 1997-08-06 2001-08-28 ミレニウム バイオセラピューティクス インク． Ｔａｎｇｏ−７１、Ｔａｎｇｏ−７３、Ｔａｎｇｏ−７４、Ｔａｎｇｏ−７６およびＴａｎｇｏ−８３核酸分子およびポリペプチド
JP3868740B2 (ja) * 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
WO2000000609A2 (fr) * 1998-06-29 2000-01-06 Incyte Pharmaceuticals, Inc. Molecules associees a l'apoptose

Also Published As

Publication number Publication date
AU8693598A (en) 1999-03-01
TR200000331T2 (tr) 2000-05-22
EP1012333A4 (fr) 2003-01-02
BR9811865A (pt) 2000-08-15
CA2296598A1 (fr) 1999-02-18
KR20010022741A (ko) 2001-03-26
WO1999007893A1 (fr) 1999-02-18
CN1270637A (zh) 2000-10-18
JP2001512698A (ja) 2001-08-28

Similar Documents

Publication Publication Date Title
WO1999007893A1 (fr) ISOLEMENT D'UN NOUVEAU GENE p23 DU FACTEUR DE SENESCENCE
EP0804451A1 (fr) Marqueur du cancer des poumons
WO2003101388A2 (fr) Element 11 famille 7 de support de solute humain (hslc7a11)
Fernandez-Pol et al. A growth factor-inducible gene encodes a novel nuclear protein with zinc finger structure.
JP2002525067A (ja) レプチン誘導遺伝子
JP2003508030A (ja) 新規ポリペプチドおよびそれをコードする核酸
EP1048727B1 (fr) Gene codant une proteine transmembranaire
US6987004B1 (en) Genes integrating signal transduction pathways
KR100869190B1 (ko) 암세포 증식 조절에 유용한 폴리뉴클레오티드
JPWO2000029571A1 (ja) 新規膜貫通蛋白質をコードする遺伝子
US6586581B1 (en) Prolactin regulatory element binding protein and uses thereof
US20050196753A1 (en) Human coactivator-associated arginine methyltransferase 1 (hCARM1)
AU776341B2 (en) Meg-1 protein
AU762987B2 (en) Chondrosarcoma associated genes
JP2006525031A (ja) Ａｃｈｅｒｏｎ発現の制御方法
AU2319700A (en) Meg-4 protein
US6342594B1 (en) Nucleic acid which is upregulated in metastatic human tumor cells
US7309783B2 (en) Mammalian early developmental regulator gene
WO2002026809A1 (fr) Nouveau polypeptide, proteine transmembranaire 35.31 possedant un domaine permettant la duplication de facteurs de croissance epidermique, et polynucleotide codant ce polypeptide
WO2001021649A2 (fr) Acides nucleiques codant pour des proteines de liaison de l'element de reponse a la vitamine d, produits connexes et leurs methodes d'utilisation
US20030109016A1 (en) TSLL1 gene
US20020123092A1 (en) Regulatory elements from RP1 gene and uses thereof
Mattei et al. Human CREM Gene: Evolutionary Conservation, Chromosomal Localization, and Inducibility of the Transcript’
WO2001049734A1 (fr) Nouveau polypeptide, proteine plp 10, et polynucleotide codant pour ce polypeptide
WO2001079467A2 (fr) Identification d'une nouvelle nadph-oxydase renale

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20021113

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030116